FDMT - שווי פעילות לרווח לפני ריבית, מסים ופחת 4D Molecular Therapeutics

4D Molecular Therapeutics (FDMT) specializes in developing gene delivery systems for the treatment of vision pathologies and cardiology using a single core technology. The price history on GURU.Markets, where the EV/EBITDA ratio equals 0.00, links these developments to the production cycle in California sterile laboratories with autonomous power supplies. Business prospects are bolstered by high demand for drugs treating macular degeneration.

EV/EBITDA measures the total enterprise value, including net debt, relative to operating profit before depreciation and amortization. The formula is sensitive to debt load and capital expenditures, allowing for the determination of an asset's fair value. By analyzing the EV/EBITDA ratio of a company on the GURU.Markets platform, an investor identifies fundamental support levels. Strategic partnerships of 4D Molecular Therapeutics (FDMT) in gene therapy reduce operational risks, which directly stabilizes this metric.